Accellix was founded based on creating a rapid, easy-to-use, automated cell phenotyping platform tailored for point of need environments, focusing on cell therapy and blood characterization. This platform brings next-generation analytical capabilities to cell therapy development and manufacturing QC, enabling the measurement of critical quality attributes at every QC phenotyping interrogation point throughout the manufacturing process and the release of cell therapy products – when and where required. The application of this platform also includes the characterization of blood-derived apheresis products used as source material for oncology, autoimmune and inflammatory disease research, for donor screening, and for the development and manufacture of advanced therapies. Currently, these assays are performed on standard flow cytometers in centralized labs which require skilled technicians, high maintenance, a separate lab space, and a long turnaround time.